|
Statement regarding PBS access to alendronate for osteoporosis patients
Merck Sharp & Dohme disagrees with the decision of the Pharmaceutical Benefits Advisory Committee (PBAC) to reject the company's submission to widen access to alendronate to all patients with clinically defined osteoporosis over the age of 70 years... more »
CanTeen NSW
In 1985, at the Prince of Wales Hospital, Sydney, six young people were being treated for cancer. They were in an adult hospital and decided they’d go out for a day with some health professionals and talk about how it felt and how they could connect as adolescents in such a foreign environment.... more »
|
|
2008 Advancing BioBusiness Award Winners Announced
Two of Australia’s leading life scientists have been chosen from a highly competitive field of candidates to take part in an initiative by Merck Sharp & Dohme and Advance to boost the capability of the country’s burgeoning biopharmaceutical industry.
Antisense Therapeutics Ltd (ASX code: ANP) Research Director Dr Christopher Wraight and DendriMed Research Director Dr Raisa Monteiro have been selected as joint winners of the 2008 Advancing BioBusiness Award, which aims to expand vital global connections for Australian science and foster more international business for local life sciences companies click here» |
NEWSROOM
The latest information from Merck Sharp & Dohme news and events... more »
|
